Clinical outcome and prognostic survival factors in patients with advanced renal cell carcinoma treated with very low-dose interleukin-2, interferon-α, and tegafur-uracil: A single-institution experience

International Journal of Clinical Oncology

Volumn 13, Issue 3, 2008, Pages 257-262

  Kobayashi, Minoru ^a   Ikeda, Hitoshi ^a   Nukui, Akinori ^a   Suzuki, Kazumi ^a   Sugaya, Yasuhiro ^a   Yuzawa, Masayuki ^a   Morita, Tatsuo ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Interferon ; Interleukin 2; Renal cell carcinoma; Tegafur uracil

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON; HEMOGLOBIN; INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 2; UFT;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; DIARRHEA; DISORIENTATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEVER; FOLLOW UP; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; KIDNEY CARCINOMA; KIDNEY FAILURE; LEUKOPENIA; LIVER INJURY; LOW DRUG DOSE; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHRECTOMY; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT; SKIN MANIFESTATION; THROMBOCYTOPENIA; TREATMENT RESPONSE; VISUAL IMPAIRMENT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; TEGAFUR; URACIL;

EID: 45749090556     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-007-0752-0     Document Type: Article

References (38)

1. Atkins MB, Regan M, McDermott D (2004) Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin Cancer Res 10:6342-6634
2. Atkins MB, Sparano J, Fisher RI, et al. (1993) Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol 11:661-670
3. Atzpodien J, Lopez Hanninen E, et al. (1995) Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol 13:497-501
4. Negrier S, Escudier B, Lasset C, et al. (1998) Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 338:1272-1278
5. Ravaud A, Delva R, Gomez F, et al. Groupe Francais d'Immunotherapie (2002) Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma. Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter phase II trial from the Groupe Francais d'Immunotherapie. Cancer 95:2324-2330
6. Rosenberg SA, Lotze MT, Muul LM, et al. (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889-897
7. Dillman RO, Wiemann MC, Bury MJ, et al. (1997) Hybrid high-dose bolus/continuous infusion interleukin-2 in patients with metastatic renal cell carcinoma: a phase II trial of the National Biotherapy Study Group. Cancer Biother Radiopharm 12:5-11
8. Ravaud A, Negrier S, Cany L, et al. (1994) Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma. Br J Cancer 69:1111-1114
9. Atzpodien J, Lopez Hanninen E, Kirchner H, et al. (1995) Multi-institutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol 13:497-501
10. Buzio C, De Palma G, Passalacqua R, et al. (1997) Effectiveness of very low doses of immunotherapy in advanced renal cell cancer. Br J Cancer 76:541-544
11. Buzio C, Andrulli S, Santi R, et al. (2001) Long-term immunotherapy with low-dose interleukin-2 and interferon-alpha in the treatment of patients with advanced renal cell carcinoma. Cancer 92:2286-2296
12. Lopez Hanninen E, Kirchner H, Atzpodien J (1996) Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol 155:19-25
13. Atzpodien J, Kirchner H, Illiger HJ, et al. (2001) IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer 85:1130-1136
14. Aso Y, Tazaki H, Umeda T, Marumo K (1989) A phase II trial of S-6820 (recombinant interleukin-2) on renal cell carcinoma (in Japanese). Biotherapy 3:999-1007
15. Makower D, Wadler S, Haynes H, Schwartz EI (1997) Interferon induces thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in vivo. Clin Cancer Res 3:923-929
16. Morita T, Tokue A (1999) Biomodulation of 5-fluorouracil by interferon-alpha in human renal carcinoma cells: relationship to the expression of thymidine phosphorylase. Cancer Chemother Pharmacol 44:91-96
17. WHO handbook for reporting results of cancer treatment (1979) WHO offset publication No. 48. World Health Organization, Geneva
18. Atzpodien J, Hoffmann R, Franzke M, et al. (2002) Thirteen-year, long-term efficacy of interferon 2 alpha and interleukin 2-based home therapy in patients with advanced renal cell carcinoma. Cancer 95:1045-1050
19. Atzpodien J, Kirchner H, Jonas U, et al. (2004) Interleukin-2 and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 22:1188-1194
20. Hutson TE, Quinn DI (2005) Cytokine therapy: a standard of care for metastatic renal cell carcinoma? Clin Genitourin Cancer 4:181-186
21. Négrier S, Caty A, Lesimple T, et al. (2000) Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Français d'Immunothérapie, Fédération Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 18:4009-4015
22. Suzuki K, Nukui A, Kobayashi M, et al. (1999) A case of pulmonary metastasis from renal cell carcinoma with complete response to interferon-α and tegafur/uracil but possibly UFT-induced liver dysfunction and leukoencephalopathy-like symptoms (in Japanese). Acta Urol Jpn 45:621-624
23. Akaza H, Tsukamoto T, Onishi T, et al. (2006) A low-dose combination therapy of interleukin-2 and interferon-alpha is effective for lung metastasis of renal cell carcinoma: a multicenter open study. Int J Clin Oncol 11:434-440
24. McDermott DF, Atkins MB (2004) Application of IL-2 and other cytokines in renal cancer. Expert Opin Biol Ther 4:455-468
25. Baaten G, Voogd AC, Wagstaff J (2004) A systematic review of the relation between interleukin-2 schedule and outcome in patients with metastatic renal cell cancer. Eur J Cancer 40: 1127-1144
26. Motzer RJ, Mazumdar M, Bacik J, et al. (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma J Clin Oncol 17:2530-2540
27. Negrier S, Gomez F, Douillard JY, et al. Groupe Francais d'Immunotherapie (2005) Prognostic factors of response of failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie. World J Urol 23:161-165
28. Palmer PA, Vinke J, Philip T, et al. (1992) Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol 3:475-480
29. Fossa SD, Kramar A, Droz JP (1994) Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha. Eur J Cancer 30A:1310-1314
30. Negrier S, Escudier B, Gomez F, et al. (2002) Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie. Ann Oncol 13:1460-1468
31. Leibovich BC, Han KR, Bui MH, et al. (2003) Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 98:2566-2575
32. Atzpodien J, Royston P, Wandert T, et al. DGCIN - German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group (2003) Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer 88:348-353
33. Motzer RJ, Bacik J, Schwartz LH, et al. (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22:454-463
34. Patel NP, Lavengood RW (1978) Renal cell carcinoma: natural history and results of treatment. J Urol 119:722-726
35. Yang JC, Haworth L, Sherry RM, et al. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434
36. Motzer RJ, Hutson TE, Tomczak P, et al. (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124
37. Escudier B, Eisen T, Stadler WM, et al. (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134
38. Ryan CW, Goldman BH, Lara PN Jr, et al. (2007) Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol 25:3296-3301